TRAJECTORY: A study of the long-term impact of Kaftrio in people with cystic fibrosis
Details
- Therapeutic approach
- Observational
- Trial status
- Recruitment complete Participating Centres
- Trials Tracker ID
- TT007421
- Last updated
- 13/07/2022
A study of the long-term impact of Kaftrio treatment in people with cystic fibrosis in the real world
Study detailsThe purpose of this observational study is to collect information on the clinical characteristics (such as CFTR genotype and disease severity), treatment requirements (such as hospital visits and use of antibiotics), and quality of life of people with cystic fibrosis who are taking Kaftrio prescribed by their doctor as part of their routine care.
This is an observational study. Participants do not have to complete any additional study procedures or attend study visits, but will be asked to give informed consent for their data to be used in the study.
The data collected in this study is information that is already documented in the patient's medical records while receiving usual care as directed by their doctor and other healthcare providers.
- Phase
- Not applicable
- Length of participation
- 60 months (5 years)
- Recruitment target
- 55
- CF sponsor
- Vertex
- CF sponsor type
- Commercial
Who can take part?
- Age range
- Aged 6 years and older
- Including people
People with CF who are aged 6 years and older and eligible for treatment with Kaftrio.
- Excluding people
People with CF currently participating in interventional studies or managed access programmes will not be eligible for this study.